Results 11 to 20 of about 55,987 (284)

Vitamin C Prevents Hypogonadal Bone Loss [PDF]

, 2012
Epidemiologic studies correlate low vitamin C intake with bone loss. The genetic deletion of enzymes involved in de novo vitamin C synthesis in mice, likewise, causes severe osteoporosis. However, very few studies have evaluated a protective role of this
Brenda Smith, Harry C. Blair, Jameel Iqbal, Jay Cao, Jeffrey I. Mechanick, Jianhua Li, Lida Guo, Ling-Ling Zhu, Liu Peng, Merry Sun, Mone Zaidi, Raymond Zhou, Surinder S. Moonga, Tony Yuen, Yuanzhen Peng, Zhuan Bian   +15 more
core   +5 more sources

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density

Journal of Bone and Mineral Research, 2021
Romosozumab monoclonal antibody treatment works by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone resorption.
Kes Poole, Graham M. Treece, R. Pearson, A. Gee, M. Bolognese, J. Brown, S. Goemaere, A. Grauer, D. Hanley, C. Mautalen, C. Recknor, Y. Yang, M. Rojeski, C. Libanati, T. Whitmarsh   +14 more
semanticscholar   +1 more source

Analysis of the Degree of Information of Dental Surgeons about Antiresorptive Drugs According to the Time Since Graduation in Dentistry

Pesquisa Brasileira em Odontopediatria e Clínica Integrada, 2023
Objective: To determine the level of scientific information of dental surgeons who carry out their professional activities in Brazil about antiresorptive drugs and indicated pharmacological procedures aiming at the prevention of osteonecrosis of the jaws
Flávia Godinho Costa Wanderley Rocha, Roberto Paulo Correia de Araújo   +1 more
doaj  

Nanoroughness, Surface Chemistry and Drug Delivery Control by Atmospheric Plasma Jet on Implantable Devices [PDF]

, 2018
Implantable devices need specific tailored surface morphologies and chemistries to interact with the living systems or to actively induce a biological response also by the release of drugs or proteins.
Ambrosi, Emmanuele, Brun, Paola, Genova, Tullio, Mattei, Giovanni, Michieli, Niccol\uf2 T, Moroni, Lorenzo, Mussano, Federico, Patelli, Alessandro, Scopece, Paolo   +8 more
core   +3 more sources

Rocaglates as dual-targeting agents for experimental cerebral malaria [PDF]

, 2018
Cerebral malaria (CM) is a severe and rapidly progressing complication of infection by Plasmodium parasites that is associated with high rates of mortality and morbidity.
Ayi, Kodjo, Brown, Lauren E., Cencic, Regina, Crandall, Ian, Gros, Philippe, Kain, Kevin C., Kennedy, James M., Langlais, David, Moradin, Neda, Pelletier, Jerry, Porco, John A., Schmeing, Martin, Tarry, Michael J.   +12 more
core   +1 more source

The Use of Antidepressive Agents and Bone Mineral Density in Women: A Meta-Analysis

International Journal of Environmental Research and Public Health, 2018
Antidepressive agents are one of the fastest-growing classes of prescribed drugs. However, the effects of antidepressive agents on bone density are controversial.
J. U. Schweiger, U. Schweiger, M. Hüppe, K. Kahl, W. Greggersen, K. Jauch-Chara, Eva Fassbinder   +6 more
semanticscholar   +1 more source

Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review

Drugs, 2021
The number of patients on long-term anti-osteoporotic drug therapy is rising. Unfortunately, there are few data to guide decisions about duration of pharmacologic therapy for osteoporosis.
L. Elbers, H. Raterman, W. Lems
semanticscholar   +1 more source

Use of natural resins in repairing damaged timber beams – An experimental investigation [PDF]

, 2019
Different techniques including the application of steel elements, composite materials and polymeric resins have been used in the past to repair damaged timber beams.
Benedetti, G, Corradi, Marco, Ede, A N, Osofero, A I   +3 more
core   +3 more sources

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Journal of Bone Oncology, 2019
Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj   +1 more source

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Bone Reports, 2019
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing ...
Chad L. Deal, Bruce H. Mitlak, Yamei Wang, Lorraine A. Fitzpatrick, Paul D. Miller   +4 more
doaj   +1 more source